Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial
Nature Medicine, Published online: 26 October 2026; doi:10.1038/s41591-026-04742-7 As presented at the ESMO Congress 2026: In the global phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy in patients with resectable and borderline resectable non-small-cell lung cancer, followed by multidisciplinary reassessment, enabled surgery in most patients, leading to encouraging pathological…
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
